N. prodotti: 0
Totale ordine: € 0,00
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,118
Online ISSN 1827-1634
GnRH NEURON BIOLOGY AND CONGENITAL HYPOGONADOTROPIC HYPOGONADISM
Giovanni CORONA 1, Elisa MASEROLI 2, Giulia RASTRELLI 2, Davide FRANCOMANO 3, Antonio AVERSA 3, 4, Geoffrey I. HACKETT 5, Simona FERRI 1, Alessandra SFORZA 1, Mario MAGGI 2
1 Endocrinology Unit, Azienda USL di Bologna, Medical Department, Maggiore-Bellaria Hospital, Bologna, Italy; 2 Unit of Sexual Medicine and Andrology, Department of Experimental, Clinical and Biomedical Sciences, University of Florence, Florence, Italy; 3 Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy; 4 Department of Experimental and Clinical Medicine, Magna Graecia University, Catanzaro, Italy; 5 Good Hope Hospital, Sutton Coldfield, UK
BACKGROUND: The aim of this paper is to summarize the available evidence supporting the link between late onset hypogonadism (LOH) and associated common clinical illnesses, focusing on metabolic diseases. The possible benefits or risks related to testosterone replacement therapy (TRT) in these conditions will also be analyzed.
METHODS: An extensive Medline search was performed.
RESULTS: LOH is closely associated with a worse metabolic profile and a higher cardiovascular risk. The relationship between hypogonadism obesity and insulin resistance is complex and bidirectional. Emerging evidence suggests a positive role of TRT in improving body composition and metabolic outcomes in subjects with LOH.
CONCLUSIONS: Despite the aforementioned data, it is not completely known whether reduced testosterone levels in elderly males might play a direct pathogenetic role in these conditions or whether low T and associated morbidities are concomitant conditions, both associated with the aging process. Further and longer studies are advisable to confirm the preliminary results.